Carrierwave is a technology acquired as part of the acquisition of New River Pharmaceuticals ('NRP') and is used in VYVANSE. Since its acquisition, Shire scientists have significantly improved the understanding and breadth of this technology. It potentially allows Shire to develop new chemical entities ('NCE's), but with less risk as the products will be based on the understanding of known products which we seek to improve.
Central Nervous System
Chronic Kidney Disease disrupts the delicate interplay between the body's levels of calcium, parathyroid hormone ('PTH'), and vitamin D, leading to hyperphosphataemia. Over time, hyperphosphataemia can ultimately lead to calcification in the heart, lung, and some arteries.1 Accumulating evidence shows that hyperphosphataemia contributes to cardiovascular disease, which accounts for almost half of all deaths among dialysis patients.2 Studies have shown that cardiovascular mortality in dialysis patients aged 25–34 years is more than five times greater than that in people aged 65–74 in the general population.3
US Food and Drug Administration
Gross Domestic Product
Oral therapies usually conducted in healthy human volunteers to determine if a drug candidate is safe for the more extensive testing.
Clinical trials conducted in patients with relevant disease to assess the safety and efficacy of the trust candidate.
Clinical trials conducted in the target patient population to comprehensively assess the safety and efficacy of the drug candidate.
